Company Profile
Galectin Therapeutics Stock Price, News & Catalysts
- Ticker:
- GALT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.76 USD (+0.80%)
Close
Last updated: October 6, 2026
159M USD
Market cap
Why the stock is moving
The latest company update was “Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026”. GALT changed 0.80% and closed at $3.76 on Oct 6, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Galectin-Targeted Drug Developer
Galectin Therapeutics develops therapies that inhibit galectin proteins involved in fibrosis, inflammation, and cancer. Its clinical strategy is centered on galectin-3, a protein associated with tissue scarring and disease progression.
Belapectin Lead Candidate
Belapectin is a complex carbohydrate drug designed to bind galectin-3. The candidate is being developed for patients with MASH cirrhosis and portal hypertension, where preventing complications could delay clinical deterioration.
Portal Hypertension Strategy
The program focuses on patients with compensated cirrhosis who have not yet developed esophageal varices. By targeting an earlier disease stage, Galectin aims to reduce the formation of varices and other consequences of portal hypertension.
NAVIGATE Clinical Foundation
The Phase 2b/3 NAVIGATE program generated clinical and biomarker data used in discussions with the FDA. Those interactions informed the design of a new registrational Phase 3 study focused on a more clearly defined patient population and endpoint strategy.
Future catalysts
- Submission of the registrational Phase 3 protocol for belapectin to the FDA in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Galectin Therapeutics (GALT)?
Galectin Therapeutics (GALT) most recently closed at 3.76 USD, a +0.80% move versus the previous session.
What is the market cap of Galectin Therapeutics (GALT)?
Galectin Therapeutics currently has a market capitalization of 159M USD on BioPharmSignal.
What does Galectin Therapeutics do?
Galectin-Targeted Drug Developer Galectin Therapeutics develops therapies that inhibit galectin proteins involved in fibrosis, inflammation, and cancer. Its clinical strategy is centered on galectin-3, a protein associated with tissue scarring and disease progression. Belapectin Lead Candidate Belapectin is a complex carbohydrate drug designed to bind...
On which exchange is GALT stock listed?
Galectin Therapeutics (GALT) is associated with NASDAQ, United States, Biopharma.
What is Galectin-Targeted?
Galectin-Targeted Drug Developer Galectin Therapeutics develops therapies that inhibit galectin proteins involved in fibrosis, inflammation, and cancer.
Which conditions is Galectin Therapeutics targeting with Galectin-Targeted?
Galectin Therapeutics is associated with cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does Galectin Therapeutics describe recent progress with Galectin-Targeted?
Submission of the registrational Phase 3 protocol for belapectin to the FDA in the third quarter of 2026.
What is Drug?
Galectin-Targeted Drug Developer Galectin Therapeutics develops therapies that inhibit galectin proteins involved in fibrosis, inflammation, and cancer.